First Patient Dosed in Phase 1 Trial of Protollin for Early Alzheimer’s

First Patient Dosed in Phase 1 Trial of Protollin for Early Alzheimer’s

314139

First Patient Dosed in Phase 1 Trial of Protollin for Early Alzheimer’s

I-Mab Biopharma announced that the first patient has been dosed in the U.S.-based Phase 1 trial of its intranasal immunotherapy agent Protollin — an investigational medication being developed to treat those with early Alzheimer’s disease. The U.S. Food and Drug Administration approved the company’s request for this safety and early efficacy study in July. “This is an important milestone in the quest to develop novel treatments for patients suffering from Alzheimer’s disease and we look forward to…

You must be logged in to read/download the full post.